

Supplementary Material B

Evaluation of Parkinson's disease early diagnosis using single-channel EEG features and auditory cognitive assessment

Lior Molcho^{†1*}, Neta B. Maimon^{†1,2}, Neomi Hezi⁵, Talya Zeimer¹, Nathan Intrator^{1,3,4}, Tanya Gurevich^{4,5,6}

Demographic results

To ensure that the groups were well-balanced we compared some demographic characteristics of each group. Table 1 presents descriptive information regarding the motor symptoms side. The table presents the group association, gender and laterality of the motor symptoms of the patients. Data of 29 patients was collected, 3 additional patients did not have this data in their record.

| Study group | PD medications | Count |
|----------------|-----------------------------------|-------|
| Negative | Sinemet CR (Levodopa / carbidopa) | 1 |
| | Propranolol | 1 |
| | Rasagiline | 1 |
| | Amantadine | 1 |
| Positive | Sinemet CR (Levodopa / carbidopa) | 4 |
| | Rasagiline | 9 |
| | Amantadine | 8 |
| | Levodopa/ carbidopa/entacapone | 2 |
| | levodopa/carbidopa | 8 |
| | levodopa/ benserazide | 1 |

¹ Neurosteer Inc, NYC, New York, USA

² School of Psychological Sciences, Tel Aviv University, Tel Aviv, Israel

³ Blavatnik School of Computer Science, Tel-Aviv University, Tel-Aviv, Israel;

⁴ Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel

⁵ Movement Disorders Unit, Neurological Institute, Tel Aviv Sourasky Medical Center.

⁶ Faculty of Medicine, Tel-Aviv University, Israel

| Pramipexol | 2 |
|--------------------------------|---|
| Losartan + Hydrochlorothiazide | 1 |
| ISOSORBIDE MONONITRATE | 1 |
| Propranolol | 1 |
| Gabapentin | 1 |
| Mirtazapine | 1 |
| Aspirin | 1 |
| Rasagiline | 1 |
| Simvastatin | 1 |
| Losartan | 1 |
| Trihexyphenidyl | 1 |

Table 1. PD medications given at the time of the auditory test for patients holding a valid F-DOPA test result.

| Study group | Gender | Motor symptom side | Count |
|-------------|--------|--------------------|-------|
| Negative | Female | Bilateral | 1 |
| | | L | 1 |
| | | R | 2 |
| | Male | Bilateral | 1 |
| Positive | Female | Bilateral | 4 |
| | | L | 2 |
| | | R | 5 |
| | Male | Bilateral | 4 |
| | | L | 2 |
| | | R | 7 |

Table 2. Motor symptom laterality information for patients holding a valid F-DOPA test result.

Bayesian results

Quantitative analysis using Bayesian Mann-Whitney U tests was performed to determine the similarity between the groups. This follow-up analysis was conducted using a data augmentation algorithm with 5 chains of 1000 iterations. We report the BF_{01} (i.e., the null hypothesis that H0 is not different from H1) of the Bayesian U tests between controls vs. negative; and positive vs. unknown, and the BF_{10} (i.e., the hypothesis that H0 is different from H1) of the Bayesian U tests between control vs. positive; and control vs. unknown groups.

Bayesian Mann-Whitney U tests revealed strong evidence that the predicted results of the control group differ from positive F-DOPA patients (BF₁₀ = 121.88, W = 385, R² = 1.04), and presented moderate evidence of similarity to the negatively labeled F-DOPA group (BF₀₁ = 2.97, W = 116, R² = 1.21). The group with unknown labels, who were all given positive predictor results, was strongly evident to differ from the control group (BF₁₀ = 149.48, W = 550, R² = 1.032), and showed moderate evidence of similarity to the positive group (BF₀₁ = 2.145, W = 98, R² = 1). The U tests outputs and figures are presented in tables 2-5 and figures 1-4.

| | $\mathbf{BF_{01}}$ | \mathbf{W} | \mathbb{R}^{2} |
|---------------------------------|--------------------|--------------|------------------|
| Prediction healthy vs. negative | 2.793 | 116.000 | 1.028 |

Table 2. Bayesian Mann-Whitney U test for prediction healthy vs. negative groups.




Figure 1. Inferential plots prediction healthy vs. negative groups prior and posterior.

| | BF10 | W | R ² |
|---------------------------------|---------|---------|----------------|
| Prediction healthy vs. positive | 121.881 | 385.000 | 1.043 |

Table 3. Bayesian Mann-Whitney U test of prediction healthy vs. positive groups.




Figure 2. Inferential plots prediction healthy vs. positive groups prior and posterior.

| | BF ₁₀ | \mathbf{W} | R ² |
|--------------------------------|------------------|--------------|----------------|
| Prediction healthy vs. unknown | 149.481 | 550.000 | 1.032 |

Table 4. Bayesian Mann-Whitney U test for prediction healthy vs. unknown groups.




Figure 3. Inferential plots prediction healthy vs. unknown groups prior and posterior.

| | BF ₀₁ | W | R ² |
|---------------------------------|------------------|--------|----------------|
| Prediction positive vs. unknown | 2.145 | 98.000 | 1.000 |

Table 5. Bayesian Mann-Whitney U test for prediction positive vs. unknown groups.




Figure 4. Inferential plots prediction positive vs. unknown groups prior and posterior.